Search PubMedSearch

PubMed · 41001005

Orthobunyavirus neurovirulence is a complex trait involving all three genome segments.

Abstract

La Crosse orthobunyavirus (LACV) is a tri-segmented negative sense RNA virus and is the leading cause of pediatric arboviral encephalitis in the USA. The viral factors that mediate LACV's ability to replicate and cause damage and disease in the brain (neurovirulence) are not fully understood. We previously characterized the neurovirulence of LACV and closely related Inkoo virus (INKV) and discovered they have opposing neurovirulence phenotypes in mice and human neuronal cells: LACV has high neurovirulence and INKV has low neurovirulence. We therefore generated reassortant viruses between LACV and INKV to map the genome segments that mediate LACV's high neurovirulence phenotype. We recovered all six possible reassortant viruses of the L, M, and S genome segments using coinfection and reverse genetics approaches. We evaluated the neurovirulence of these reassortant viruses in mice in vivo and in human neuronal cells in vitro. Our results show that no single LACV genome segment alone was sufficient to cause wildtype LACV-like neurological disease in mice, and in fact all six reassortant viruses were attenuated from wildtype LACV. We found that the LACV M and S segments together were the primary drivers of neurological disease in mice, whereas the LACV L segment played a minor role. Our in vitro results indicate that the LACV M segment is crucial for efficient replication in neurons, but the LACV L segment appears to mediate slightly more efficient neuronal replication than the INKV L segment. The LACV M and S segments together induced wildtype LACV-like levels of neuronal death, indicating the LACV M and S are the primary mediators of neuronal death, and the L segment is not required. Together, these results indicate that LACV neurovirulence is a complex trait mediated by viral proteins on all three genome segments.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Matthew J Abbott, Christina R Norsten, Sarah L Anzick, Craig Martens, Clayton W Winkler, Alyssa B Evans. 2025-09-16. Orthobunyavirus neurovirulence is a complex trait involving all three genome segments.. https://doi.org/10.1101/2025.09.16.676581

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article